Navigation Links
DATATRAK Launches New Web Site
Date:8/26/2009

CLEVELAND, Aug. 26 /PRNewswire-FirstCall/ -- DATATRAK International, Inc. (OTCQX: DATA), a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced the launch of the Company's new web site. Unveiled at the Annual Shareholder Meeting, the interactive web site is a continuation of DATATRAK's singular vision for product and service delivery - DATATRAK ONE(TM).

The web site is available at http://www.datatrak.net and delivers content in multiple formats: product videos, informational downloads, RSS feeds, Twitter and email. Visitors to the web site can find out how to empower Clinical Users and Service Providers with the components necessary for efficiently conducting, delivering and managing clinical trials.

"As a key component of the DATATRAK ONE(TM) initiative, the launch of the web site will provide an interactive experience that allows users to explore the breadth of the DATATRAK offerings," said Laurence Birch, DATATRAK's Chairman of the Board.

About DATATRAK International, Inc.

DATATRAK International, Inc. is a worldwide technology company focused on the provision of multi-component eClinical solutions and related services for the clinical trials industry. We operate under the concept of DATATRAK ONE(TM), which encompasses our unique, single platform technology. The singular architecture of our DATATRAK eClinical(TM) product suite has been embraced by clients around the globe for its ability to effectively manage clinical trials through an integrated multi-component, comprehensive solution. The Company delivers a complete portfolio of software products that were created in order to accelerate clinical research data from investigative sites to clinical trial sponsors and ultimately the FDA, faster and more efficiently than manual methods or loosely integrated technologies. DATATRAK's eClinical(TM) software suite can be deployed worldwide through an ASP offering or in a licensed Enterprise Transfer model that fully empowers its clients. The DATATRAK software suite and its earlier versions have successfully supported hundreds of international clinical trials involving thousands of clinical research sites and encompassing tens of thousands of patients in 59 countries. DATATRAK International, Inc.'s product suite has been utilized in some aspect of the clinical development of 16 drugs and one medical device that have received regulatory approval from either the United States Food and Drug Administration or counterpart European bodies. DATATRAK International, Inc. has offices located in Cleveland, Ohio, and Bryan, Texas. Visit the DATATRAK International, Inc. web site at www.datatrak.net.

Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management's expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors (including those specified below) which are difficult to predict and, in many instances, are beyond the control of the Company. Factors that may cause actual results to differ materially from those in the forward-looking statements include the limited operating history on which the Company's performance can be evaluated; the ability of the Company to continue to enhance its software products to meet customer and market needs; fluctuations in the Company's quarterly results; the viability of the Company's business strategy and its early stage of development; the timing of clinical trial sponsor decisions to conduct new clinical trials or cancel or delay ongoing trials; the Company's dependence on major customers; government regulation associated with clinical trials and the approval of new drugs; the ability of the Company to compete in the emerging EDC market; losses that potentially could be incurred from breaches of contracts or loss of customer data; the inability to protect intellectual property rights or the infringement upon other's intellectual property rights; the costs associated with maintaining and/or developing two product suites; and general economic conditions such as the rate of employment, inflation, interest rates and the condition of capital markets. This list of factors is not all-inclusive. In addition, the Company's success depends on the outcome of various strategic initiatives it has undertaken, all of which are based on assumptions made by the Company concerning trends in the clinical research market and the health care industry. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE DATATRAK International, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Advance Research Associates Joins DATATRAKs CRO Connect Program(TM)
2. DATATRAK Announces New Products and Features at DIA San Diego
3. DATATRAK Announces Receipt of NASDAQ Panel Decision to Delist Common Shares
4. DATATRAK International, Inc. Announces First Quarter Results for 2009
5. German CRO clinicalprojects international GmbH Becomes Newest Member of DATATRAKs CRO Connect Program(TM)
6. Keypoint Joins DATATRAKs CRO Connect Program(TM)
7. NASDAQ Panel Grants Extension to DATATRAK for Continued Listing on the NASDAQ Capital Market
8. DATATRAK International, Inc. Announces Fourth Quarter and Full Year Results for 2008
9. DATATRAK International, Inc. Announces the Return of Chris Wilke as Vice-President of R&D and the Issuance of a Patent
10. DATATRAK Announces Retirement of Chief Executive Officer
11. DATATRAK International, Inc. Receives Notice from NASDAQ
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2017)... ... 26, 2017 , ... IndustryArchive.Org . is announcing a new way for ... will now only pay for B.A.N.T. quality sales leads based on the Sellers decision ... the new reality that B2B buyers are controlling the sales process via the Internet ...
(Date:2/26/2017)... , ... February 26, 2017 , ... ... disease (PD) in persons with a specific LRRK2 mutation, according to a study ... Previous studies have provided evidence of a link between pesticides and incidence of ...
(Date:2/24/2017)... ... February 24, 2017 , ... Only two months after the official ... (ILTM) show in Cannes (France), XO Private has initiated a second print-run of its ... measures almost a metre across when open, weighs in at more than six kilos, ...
(Date:2/24/2017)... ... 24, 2017 , ... The Smart Machine Age is here, and it’s disrupting ... percent of all jobs in the United States may be taken over by technology ... the aggressive know-it-all who steamrolls over colleagues is drawing to a close. Success will ...
(Date:2/24/2017)... Australia (PRWEB) , ... February 24, 2017 , ... The ... AU) offers Erik Schanssema ’s true account of his paramedic experiences. Schanssema describes ... stress disorder and his attempts to overcome them. , Schanssema, initially unsure of ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... REDWOOD CITY, Calif., Feb. 23, 2017 Nevro Corp. ... innovative evidence-based solutions for the treatment of chronic pain, today ... ended December 31, 2016. 2016 Accomplishment & ... the full year 2016, an increase of 228% as reported, ... million for 2016, an increase of 612% over the prior ...
(Date:2/23/2017)... 23, 2017 Research and Markets has announced ... Strategies - 2016" report to their offering. ... The latest research Oesophageal Cancer ... and benchmarks in the global Oesophageal Cancer market. The ... are the key drugs marketed for Oesophageal Cancer and their clinical ...
(Date:2/23/2017)... , Feb. 23, 2017 Regulus ... the discovery and development of innovative medicines targeting microRNAs, ... year 2016 financial results on Thursday, March 2, 2017 ... a conference call and webcast on March 2, 2017 ... and full year 2016 financial results and provide a ...
Breaking Medicine Technology: